INFINITY PHARMACEUTICALS INC (INFI)
US45665G3039 - Common Stock
INFINITY PHARMACEUTICALS INC
NASDAQ:INFI (9/13/2023, 7:17:37 PM)
After market: 0.04 0 (-10.51%)0.0447
-0.04 (-46.98%)
Company Profile
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Company Info
INFINITY PHARMACEUTICALS INC
1100 Massachusetts Avenue, Floor 4
Cambridge MASSACHUSETTS 02138
P: 16174531000.0
CEO: Adelene Q. Perkins
Employees: 30
Website: https://www.infi.com/
INFI News
7 hours ago - TheNewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFIWHY: NEW YORK, NY - (NewMediaWire) - September 24, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the important October 16, 2023 lead plaintiff deadline.
13 hours ago - NewMediaWireROSEN, LEADING INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFISearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
2 days ago - Faruqi & Faruqi, LLPINFINITY INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Infinity To Contact Him Directly To Discuss Their Options/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Infinity Pharmaceuticals, Inc....
2 days ago - Bragar Eagel & SquireBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, Shift4, and Comerica and Encourages Investors to Contact the Firm3 days ago - TheNewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFIWHY: NEW YORK, NY - (NewMediaWire) - September 21, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5, 2022 and July 24, 2023, both dates inclusive (the “Class Period”), of the important October 16, 2023 lead plaintiff deadline.
3 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI)....
INFI Twits
Here you can normally see the latest stock twits on INFI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
